SITAGLIPTIN PHOSPHATE 50mg. IP + METFORMIN 1000mg. IP

A combination of two oral antihyperglycemic drugs that are used in the management of type 2 diabetes. A well-tolerated, efficacious, weight-neutral oral antidiabetic agent, with a low incidence of hypoglycemia. (Sreevidya Subbarayan, 2011) Improves the glycemic parameters of HbA1c, fasting glucose, and postprandial glucose in patients with type 2 diabetes. (Gallwitz, 2007) A viable treatment option for patients who prefer an alternative to insulin injection. (Mingqian He, 2021) More effective than either drug alone for the control of blood glucose in patients with type 2 diabetes. (Ping Shi, 2022) Provides superior glycemic improvement as compared with metformin monotherapy in type 2 diabetes patients. (C Reasner, 2011) Shows greater improvements in glycemic control than pioglitazone in patients with type 2 diabetes and moderate-to-severe hyperglycemia. (A Pérez-Monteverde, 2011)